Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability OutcomesA Randomized Clinical Trial

JAMA
April 14, 2020, Vol 323, No. 14, Pages 1327-1420
http://jama.jamanetwork.com/issue.aspx

 

Original Investigation
Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability OutcomesA Randomized Clinical Trial
Grace L. Chen, MD, MPH; Emily E. Coates, PhD; Sarah H. Plummer, CRNP; et al.
has active quiz
JAMA. 2020;323(14):1369-1377. doi:10.1001/jama.2020.2477
This clinical trial tested whether the chikungunya virus–like particle vaccince was safe for participants living in chikungunya endemic areas.
Editorial
A New Vaccine for Chikungunya Virus
Kenneth A. Stapleford, PhD; Mark J. Mulligan, MD
Research Letter
Presumed Asymptomatic Carrier Transmission of COVID-19
Yan Bai, MD; Lingsheng Yao, MD; Tao Wei, MD; et al.
free access has active quiz has audio
JAMA. 2020;323(14):1406-1407. doi:10.1001/jama.2020.2565
This study describes possible transmission of novel coronavirus disease 2019 (COVID-19) from an asymptomatic Wuhan resident to 5 family members in Anyang, a Chinese city in the neighboring province of Hubei.
Audio Interview: COVID-19 Update With NIAID’s Anthony Fauci, MD; March 6, 2020
Clinical Review Audio: Update on Coronavirus: March 6, 2020, by NIAID’s Anthony Fauci, MD
Clinical Review Audio: COVID-19 in Seattle: Clinical Features and Managing the Outbreak
Audio Interview: Coronavirus Testing – March 16 Q&A with the CDC’s Jay Butler, MD
Editorial
Editorial Concern—Possible Reporting of the Same Patients With COVID-19 in Different Reports
Howard Bauchner, MD; Robert M. Golub, MD; Jody Zylke, MD